{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:57:52Z","timestamp":1776722272450,"version":"3.51.2"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"DOI":"10.7759\/cureus.92043","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:48:37Z","timestamp":1757587717000},"source":"Crossref","is-referenced-by-count":1,"title":["FDA-Approved HIV-1 Capsid Inhibition With Lenacapavir: A Paradigm Shift in Pre-exposure Prophylaxis"],"prefix":"10.7759","author":[{"given":"Kashaf","family":"Sanaullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Haseeb","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00187-25","article-title":"Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir","volume":"16","author":"Hansen D","year":"2025","unstructured":"Hansen D, Hendricks MR, Chang S, et al.. Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir. mBio. 2025, 16:e0018725. 10.1128\/mbio.00187-25","journal-title":"mBio"},{"key":"ref2","unstructured":"Yeztugo\u00ae (lenacapavir) is now the first and only fda-approved hiv prevention option offering 6 months of protection. (2025). Accessed. August 09, 2025: https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-preventi...."},{"key":"ref3","unstructured":"Fda approval of injectable lenacapavir marks progress for hiv prevention. (2025). Accessed. August 09, 2025: https:\/\/www.who.int\/news\/item\/19-06-2025-fda-approval-of-injectable-lenacapavir-marks-progress-for-hiv-prevention."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker LG","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, et al.. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024, 391:1179-92. 10.1056\/NEJMoa2407001","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley CF","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, et al.. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025, 392:1261-76. 10.1056\/NEJMoa2411858","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/405946-fda-approved-hiv-1-capsid-inhibition-with-lenacapavir-a-paradigm-shift-in-pre-exposure-prophylaxis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:48:38Z","timestamp":1757587718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/405946-fda-approved-hiv-1-capsid-inhibition-with-lenacapavir-a-paradigm-shift-in-pre-exposure-prophylaxis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.92043","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}